Jonathan Davis, MD, MPHS
@jonathandavishf.bsky.social
Director @sfhealthnetwork HF Program Zuckerberg SF General Hospital @zsfgcare @ucsfcardiology. New Dad x2! Alum @WUSTLmed⬅️ @UCSFmedicine⬅️ @cornell he/his/him
9/29 I start at Mercy in St. Louis! After reflection & emotional debate, we’ve moved to STL. Working at ZSFG/UCSF has been a profound privilege. The community, patients, & colleagues gave me more than I can ever express. Please know how grateful I am to have been part of this extraordinary team.
Honored beyond words to receive the 2025 @ucsfmedicine.bsky.social at @zsfgcare.bsky.social Exceptional Physician Award. It is an incredible privilege to work alongside everyone across the SFHN. Thank you!
Short & sweet! Check out our review of #SGLT2i & #GLP1RA in #HeartFailure! Great work Jose Lopez & team! @ucsfcardiology.bsky.social @amitgoyalmd.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jimjanuzzi.bsky.social @sjgreene-md.bsky.social www.uscjournal.com/articles/sho...
The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF. Since 2008, regulatory agencies have required cardiovascular safety trials
uscjournal.com
NEW! Patients versions of the #Hypertension guidelines Need clear, reliable guidance for your patients with hypertension? The ESC has just released the patient-friendly version of its 2024 ESC Guidelines on management of elevated blood pressure and hypertension.
#SGLT2i & #GLP1RA; not just for the heart... or kidneys... or diabetes! In ppl w DM2, GLP-1RAs & SGLT2is were associated w ⬇️ risk of Alzheimer disease & related dementias vs other glucose-lowering drugs. @robmentz.bsky.social @jama.com @noshreza.bsky.social @jimjanuzzi.bsky.social ja.ma/3E3vWRn
GLP-1RAs and SGLT2is for Type 2 Diabetes and Alzheimer Disease
This population-based cohort study examines the association of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors with the risk of Alzheimer disease and related de...
ja.ma
Thank you @sfchronicle.com for sharing Pamela's incredible journey from homelessness/addiction to ultimately 💓 transplant! Hopefully her story is can inspire pts & providers alike. @zsfgcare.bsky.social @ucsfhealth.bsky.social www.sfchronicle.com/sf/article/h...
She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant
She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant.
sfchronicle.com
Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink. @natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social nature.com/articles/s44...
New and future heart failure drugs - Nature Cardiovascular Research
Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...
nature.com
Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social www.jointcommission.org/resources/aw...
Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social www.jointcommission.org/resources/aw...
Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink. @natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social nature.com/articles/s44...
New and future heart failure drugs - Nature Cardiovascular Research
Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...
nature.com
Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation. @jaccjournals.bsky.social www.sciencedirect.com/science/arti...
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction
Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…
sciencedirect.com
Management of Iron Deficiency in Heart Failure: Practical Considerations & Implementation of Evidence-Based Iron Supplementation #CardioSky #JACCHF @jaccjournals.bsky.social @robmentz.bsky.social @dranulala.bsky.social @hfsa.bsky.social @accintouch.bsky.social www.jacc.org/doi/10.1016/...
Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD #UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social vimeo.com/1032042870/2...
2024 QLA Equity: Zuckerberg San Francisco General Hospital/San Francisco Health Network
This is "2024 QLA Equity: Zuckerberg San Francisco General Hospital/San Francisco Health Network" by CAPH/SNI on Vimeo, the home for high quality videos…
vimeo.com
Jonathan Davis, MD, MPHS@jonathandavishf.bsky.social · 2y agoWe are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure
Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD #UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social vimeo.com/1032042870/2...
2024 QLA Equity: Zuckerberg San Francisco General Hospital/San Francisco Health Network
This is "2024 QLA Equity: Zuckerberg San Francisco General Hospital/San Francisco Health Network" by CAPH/SNI on Vimeo, the home for high quality videos…
vimeo.com
Jonathan Davis, MD, MPHS@jonathandavishf.bsky.social · 2y agoWe are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure
Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation. @jaccjournals.bsky.social www.sciencedirect.com/science/arti...
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction
Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…
sciencedirect.com
We are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure
No plans this weekend? Not too late to sign up for the 41st Annual #UCSF #ZSFG Advances in Heart Disease CME! We have a fantastic lineup ready to go! @accintouch.bsky.social @ahascience.bsky.social @hfsa.bsky.social @aspcardio.bsky.social virtualce.ucsf.edu/advances-in-...
41st Annual Advances in Heart Disease
virtualce.ucsf.edu
Novel ExCiTe approach aimed at improving trainee recruitment into AHFTC. Great work Edan Zitelny, Rachna Kataria & team @noshreza.bsky.social @cardionerds.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jcardfail.bsky.social @shelleyzieroth.bsky.social onlinejcf.com/article/S107...
#Spironolactone given to patients who have undergone PCI following an #AMI has no impact on ☠️ from CV causes, or on a range of CV events including new or worsening HF ( #CLEAR SYNERGY ) www.tctmd.com/news/spirono... @shelleywood.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social
Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY
(UPDATED) Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV events.
tctmd.com
Jonathan Davis, MD, MPHS@jonathandavishf.bsky.social · 2y ago1st post! The 3 rules of #GDMTWorks for #HFrEF: 1. Start more 2.⬆️doses 3. Keep them going #QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social
#LBCT #SUMMIT trial #AHA24 💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity 📎 @NEJM www.nejm.org/doi/full/10....
BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg). Watch this for one attendee’s take on the data.
1st post! The 3 rules of #GDMTWorks for #HFrEF: 1. Start more 2.⬆️doses 3. Keep them going #QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social